Global drug patents are falling like dominoes. Blockbuster medicines for diabetes, obesity, cancer, and rare diseases are losing legal protection. Indian generic manufacturers stand ready to produce cheaper versions.
But there is a catch.
Manufacturing is only half the battle. The real test lies on the road, inside the warehouse, and at the airport cargo bay. India’s pharma logistics network must now move millions of sensitive, temperature-dependent medicines safely and quickly.
The question is simple. Is India ready?
The Semaglutide Wake-Up Call
The patent cliff has already arrived. In March 2026, several Indian drugmakers launched generic versions of Semaglutide. This is the active ingredient in Wegovy and Ozempic, the blockbuster weight-loss and diabetes drugs.
Dr. Reddy’s Laboratories entered first. Zydus Lifesciences followed. Sun Pharmaceutical Industries and Glenmark also joined the race. Within weeks, over 40 Indian companies announced plans to launch more than 50 Semaglutide brands.
Prices crashed immediately. Monthly treatment costs fell from premium levels to just ₹1,800–₹4,200.
This sounds like good news for patients. And it is. But for logistics companies, it is a pressure test.
Semaglutide is not a simple pill. It comes in pre-filled injection pens and multi-dose devices. These products need strict temperature control. They must stay between 2 to 8 degrees Celsius from factory to patient.
One broken refrigerator. One delayed shipment. One hot warehouse. Any of these can destroy the medicine completely.
Why the ‘Patent Cliff’ Matters
The Semaglutide wave is just the beginning. According to the GreyB report, dozens of major drugs lose patent protection between 2026 and 2030. These include Epclusa, Vosevi, Verzenio, Rinvoq, and Kisqali. They treat cancer, liver disease, HIV, and rare genetic disorders.
Many of these are not ordinary medicines. They are biologics, injectables, and highly sensitive therapies. Some require freezing temperatures of -20 degrees Celsius. Others need precise humidity control.
Sreenivas Rao, Global Head of Supply Chain at Sun Pharmaceutical Industries, explains the scale of change. “The moment a drug like that goes off patent, it is not only the number of patients who are coming on board,” he says. “People who are not patients are also coming on board.”
That changes everything. Demand becomes unpredictable. Supply chains must scale instantly. And there is no room for error.
The Cold-Chain Gap in India
Here is the hard truth. India does not have enough refrigerated trucks.
Rao puts it bluntly. “There are three temperature zones pharma talks about. 15 to 25°C is air conditioning. 2 to 8°C is your refrigerator. -20°C is your freezer. We do not have too many trucks who can actually take 2 to 8°C.”
This is not a small problem. GLP-1 drugs like Semaglutide and Tirzepatide (Mounjaro) need exactly that range. As more Indian companies enter this space, demand for refrigerated transport will explode.
The gaps grow larger outside metro cities. Vikram Manuskhani, National Operations Head at Blue Dart, admits that Tier II, Tier III, and rural regions lack temperature-controlled storage and vehicles.
“The country needs meaningful investment in refrigerated transport, decentralised storage and monitoring systems,” Manuskhani says.
Warehouses Become High-Tech Hubs
The pressure is not only on trucks. Warehouses are transforming completely.
Gone are the days of simple storage. Today’s pharma warehouse is a compliance-driven control center. Operators must monitor temperature constantly. They must track every batch in real time. They must ensure zero deviation during loading and unloading.
Allcargo Group is strengthening its network. Suresh Narayanan, Head of Operations, says pharmaceutical supply chains are becoming “more volume intensive and compliance driven.” The company now uses integrated warehouse management systems for batch tracking and inventory control.
Kuehne+Nagel operates six HealthChain and CEIV Pharma-certified branches in India. It has temperature-controlled facilities in Bengaluru and Hyderabad. But Yuvraj Sharma, Head of Sales & Marketing, warns that consistency across the full network remains the biggest challenge.
“At a national level, the priority is now to ensure these advances are applied consistently across the full network, particularly at the first and last mile,” Sharma says.
Digital Tracking Saves Lives
The medicine is too valuable to lose. That is why digital tracking is becoming mandatory.
Kuehne+Nagel now combines carrier data with IoT-based temperature and location sensors. Their HyperCare teams monitor shipments continuously. If a temperature rises too high, they intervene before the product spoils.
This real-time visibility is not a luxury. It is a necessity. A single temperature excursion can destroy a shipment worth lakhs of rupees. Worse, it can put patients at risk.
The Europe Opportunity Adds Pressure
The India–EU Free Trade Agreement adds another layer to this story. India already exports $5.8 billion worth of pharmaceuticals to Europe every year. If the agreement removes tariffs of up to 11%, Indian generics become even more competitive.
That means more shipments. More complex medicines. And stricter EU compliance rules.
“We are seeing clients expand production in India and integrate it more deeply into their global supply networks through new and direct export lanes,” Sharma says.
Europe is not just a trade opportunity. It is a logistics challenge.
A Planned Storm, But Still a Storm
Industry leaders are not panicking. They saw this coming. Ratish Mukhoti, Head Regional SCM at Cipla, calls the patent expiry “a planned one.”
Pharma companies prepare for these moments for nearly a decade. API production ecosystems are ready. Manufacturing lines are set.
But logistics is different. You cannot stockpile cold-chain capacity years in advance. You cannot predict exactly where demand will surge. You cannot control the temperature on a rural road in July.
That is the real risk.
The Bottom Line
India built its reputation as the world’s pharmacy by making affordable generics. The next decade will test whether India can also deliver them safely.
The patent cliff offers a golden opportunity. Millions of patients worldwide will benefit from cheaper medicines. Indian companies will grow. Exports will rise.
But none of that matters if a truck lacks a working cooler. None of it matters if a warehouse loses power. None of it matters if the last mile fails.
Supply chains are no longer a support function. They are a strategic weapon. And India must upgrade that weapon now.
The medicines are ready. The trucks are not. That gap must close before the patent cliff turns into a crisis.
